| abstract |
The present invention is directed to a compound of formula I:n□ wherein the group R1 is as defined in the first paragraph of the patent application, which has valuable pharmacological properties, specifically binding to the GPR40 receptor and modulating its activity. The compounds are suitable for the treatment and prevention of diseases which may be affected by this receptor, such as metabolic diseases, in particular type 2 diabetes. |